Eleni Tzatzaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eleni Tzatzaki has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Michael Spartalis
Department of Cardiology, National and Kapodistrian University of Athens, 10679 Athens, Greece
11 shared publications Eleftherios Spartalis
Laboratory of Experimental Surgery and Surgical Research, University of Athens, Medical School, Athens, Greece
9 shared publicationsVassilis Voudris
Division of Cardiology Onassis Cardiac Surgery Center Athens Greece
5 shared publicationsAntonios Athanasiou
Department of Surgery, Mercy University Hospital, Cork, Ireland
4 shared publicationsDemetrios Moris
Department of Surgery The Ohio State University Comprehensive Cancer Center The Ohio State University Columbus Ohio
3 shared publications- Demetrios Moris
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA
3 shared publications
Latest Publications
- 1 February 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 71 (2) , 212-213
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes
- 1 February 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 71 (2) , 212-213
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 257
The emerging role of hybrid ablation for atrial fibrillation
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 257
The emerging role of hybrid ablation for atrial fibrillation
- Top Cited Papers
- 1 August 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (16) , 326
The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox
Acute and chronic excessive intracellular increase of reactive oxygen species (ROS) is involved in the development and progression of cardiovascular diseases. ROS are by-products of various oxidative physiological and biochemical processes. Sources of ROS are mitochondrial respiration, NADH/NADPH oxidase, xanthine oxidoreductase or the uncoupling of nitric oxide synthase (NOS) in vascular cells. ROS mediate various signaling pathways that underlie cardiovascular pathophysiology. The delicate equilibrium between free-radical generation and antioxidant defense is altered in favor of the former, thus leading to redox imbalance, oxidative stress, and increased cellular injury. An understanding of the pathophysiological mechanisms mediated by oxidative stress is crucial to the prevention and treatment of cardiovascular diseases.
- 1 August 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (16) , 326
Top Cited PapersThe role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox
Acute and chronic excessive intracellular increase of reactive oxygen species (ROS) is involved in the development and progression of cardiovascular diseases. ROS are by-products of various oxidative physiological and biochemical processes. Sources of ROS are mitochondrial respiration, NADH/NADPH oxidase, xanthine oxidoreductase or the uncoupling of nitric oxide synthase (NOS) in vascular cells. ROS mediate various signaling pathways that underlie cardiovascular pathophysiology. The delicate equilibrium between free-radical generation and antioxidant defense is altered in favor of the former, thus leading to redox imbalance, oxidative stress, and increased cellular injury. An understanding of the pathophysiological mechanisms mediated by oxidative stress is crucial to the prevention and treatment of cardiovascular diseases.
- 1 August 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (16) , 324
The role of reactive oxygen species in myocardial redox signaling and regulation
Reactive oxygen species (ROS) are subcellular messengers in gene regulatory and signal transduction pathways. In pathological situations, ROS accumulate due to excessive production or insufficient degradation, leading to oxidative stress (OS). OS causes oxidation of DNA, membranes, cellular lipids, and proteins, impairing their normal function and leading ultimately to cell death. OS in the heart is increased in response to ischemia/reperfusion, hypertrophy, and heart failure. The concentration of ROS is determined by their rates of production and clearance by antioxidants. Increases in OS in heart failure are primarily a result of the functional uncoupling of the respiratory chain due to inactivation of complex I. However, increased ROS in the failing myocardium may also be caused by impaired antioxidant capacity, such as decreased activity of Cu/Zn superoxide dismutase (SOD) and catalase (CAT) or stimulation of enzymatic sources, including, cyclooxygenase, xanthine oxidase (XO), nitric oxide synthase, and nonphagocytic NAD(P)H oxidases (Noxs). Mitochondria are the main source of ROS during heart failure and aging. Increased production of ROS in the failing heart leads to mitochondrial permeability transition, which results in matrix swelling, outer membrane rupture, a release of apoptotic signaling molecules, and irreversible injury to the mitochondria. Alterations of “redox homeostasis” leads to major cellular consequences, and cellular survival requires an optimal regulation of the redox balance.
- 1 August 2017
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (16) , 324
The role of reactive oxygen species in myocardial redox signaling and regulation
Reactive oxygen species (ROS) are subcellular messengers in gene regulatory and signal transduction pathways. In pathological situations, ROS accumulate due to excessive production or insufficient degradation, leading to oxidative stress (OS). OS causes oxidation of DNA, membranes, cellular lipids, and proteins, impairing their normal function and leading ultimately to cell death. OS in the heart is increased in response to ischemia/reperfusion, hypertrophy, and heart failure. The concentration of ROS is determined by their rates of production and clearance by antioxidants. Increases in OS in heart failure are primarily a result of the functional uncoupling of the respiratory chain due to inactivation of complex I. However, increased ROS in the failing myocardium may also be caused by impaired antioxidant capacity, such as decreased activity of Cu/Zn superoxide dismutase (SOD) and catalase (CAT) or stimulation of enzymatic sources, including, cyclooxygenase, xanthine oxidase (XO), nitric oxide synthase, and nonphagocytic NAD(P)H oxidases (Noxs). Mitochondria are the main source of ROS during heart failure and aging. Increased production of ROS in the failing heart leads to mitochondrial permeability transition, which results in matrix swelling, outer membrane rupture, a release of apoptotic signaling molecules, and irreversible injury to the mitochondria. Alterations of “redox homeostasis” leads to major cellular consequences, and cellular survival requires an optimal regulation of the redox balance.
- Open Access
- 14 July 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (8) , 1422-1423
Primary cardiac intimal sarcoma masquerading as mitral stenosis
Key Clinical Message: Intimal sarcomas are a very rare medical entity and usually arise from the pulmonary artery or the thoracic aorta. Sarcomas should be considered in the differential diagnosis in patients with suspected mitral valve disease. Echocardiography should be performed as early as possible to establish a prompt diagnosis and management.
- 14 July 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (8) , 1422-1423
Open AccessPrimary cardiac intimal sarcoma masquerading as mitral stenosis
Key Clinical Message: Intimal sarcomas are a very rare medical entity and usually arise from the pulmonary artery or the thoracic aorta. Sarcomas should be considered in the differential diagnosis in patients with suspected mitral valve disease. Echocardiography should be performed as early as possible to establish a prompt diagnosis and management.
- Open Access
- 16 May 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 25 (3) , 498
eComment. Noonan syndrome and biventricular hypertrophic obstructive cardiomyopathy
We read with great interest the article by Farag et al. [1]. The authors reported an interesting and challenging case of a 26-year-old male with Noonan syndrome and associated hypertrophic biventricular obstructive cardiomyopathy (HOCM). They mention that this is the first paper [2–5] regarding the association of hypertrophic cardiomyopathy and left and right ventricular outflow tract obstruction. However, is this the whole picture?
- 16 May 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 25 (3) , 498
Open AccesseComment. Noonan syndrome and biventricular hypertrophic obstructive cardiomyopathy
We read with great interest the article by Farag et al. [1]. The authors reported an interesting and challenging case of a 26-year-old male with Noonan syndrome and associated hypertrophic biventricular obstructive cardiomyopathy (HOCM). They mention that this is the first paper [2–5] regarding the association of hypertrophic cardiomyopathy and left and right ventricular outflow tract obstruction. However, is this the whole picture?
- Open Access
- 25 April 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 24 (5) , 788
eComment. Amiodarone-induced pulmonary toxicity in patients with atrial fibrillation undergoing lung resection
We read with great interest the article by Kolokotroni et al. [1]. The authors concluded that current evidence obtained from retrospective studies and meta-analyses pointed out that amiodarone is a safe agent for prophylaxis or management of atrial fibrillation after lung resection and that there is no increase in pulmonary toxicity, even when pneumonectomy patients are involved. At the same time, they mention that there is only one paper regarding the association of amiodarone and lung toxicity in post-lung surgery patients. But is this the whole picture?
- 25 April 2017
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 24 (5) , 788
Open AccesseComment. Amiodarone-induced pulmonary toxicity in patients with atrial fibrillation undergoing lung resection
We read with great interest the article by Kolokotroni et al. [1]. The authors concluded that current evidence obtained from retrospective studies and meta-analyses pointed out that amiodarone is a safe agent for prophylaxis or management of atrial fibrillation after lung resection and that there is no increase in pulmonary toxicity, even when pneumonectomy patients are involved. At the same time, they mention that there is only one paper regarding the association of amiodarone and lung toxicity in post-lung surgery patients. But is this the whole picture?
- Open Access
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (4) , 169-171
Ischemic Stroke in a Patient With Quadricuspid Aortic Valve and Patent Foramen Ovale
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (4) , 169-171
Open AccessIschemic Stroke in a Patient With Quadricuspid Aortic Valve and Patent Foramen Ovale
- Open Access
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (4) , 172-175
Parvovirus B19 Myocarditis of Fulminant Evolution
Myocarditis is an inflammation of the myocardium. Clinical presentation ranges from non-specific systematic symptoms to fulminant collapse and sudden death. Sudden death occurs at rates of 8.6-12% and cardiomyopathy at 9%. In active myocarditis, there is inflammatory cellular infiltrate with myocardial necrosis. The disease is distinguished by clinical presentation in fulminant and non-fulminant myocarditis. We present a rare case of a parvovirus B19-induced fulminant viral myocarditis in a young female. The patient presented with acute onset heart failure mimicking a myocardial infarction, followed by non-specific symptoms that had been misdiagnosed as urinary tract infection.
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (4) , 172-175
Open AccessParvovirus B19 Myocarditis of Fulminant Evolution
Myocarditis is an inflammation of the myocardium. Clinical presentation ranges from non-specific systematic symptoms to fulminant collapse and sudden death. Sudden death occurs at rates of 8.6-12% and cardiomyopathy at 9%. In active myocarditis, there is inflammatory cellular infiltrate with myocardial necrosis. The disease is distinguished by clinical presentation in fulminant and non-fulminant myocarditis. We present a rare case of a parvovirus B19-induced fulminant viral myocarditis in a young female. The patient presented with acute onset heart failure mimicking a myocardial infarction, followed by non-specific symptoms that had been misdiagnosed as urinary tract infection.
- Open Access
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (3) , 128-130
Atrial Myxoma Mimicking Mitral Stenosis
Myxoma is the most common primary cardiac tumor and is usually located in the left atrium. Clinical manifestation relies in large part on the size, location, and architecture of the tumor. There are many reports in the literature of cardiac myxomas causing syncope, embolism, even myocardial infarction. We present a rare case of a patient who underwent urgent surgical resection of a large left atrial myxoma mimicking mitral stenosis. The postoperative course of the patient was uncomplicated. One year after surgery, the patient is asymptomatic and disease-free.
- 1 January 2017
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 8 (3) , 128-130
Open AccessAtrial Myxoma Mimicking Mitral Stenosis
Myxoma is the most common primary cardiac tumor and is usually located in the left atrium. Clinical manifestation relies in large part on the size, location, and architecture of the tumor. There are many reports in the literature of cardiac myxomas causing syncope, embolism, even myocardial infarction. We present a rare case of a patient who underwent urgent surgical resection of a large left atrial myxoma mimicking mitral stenosis. The postoperative course of the patient was uncomplicated. One year after surgery, the patient is asymptomatic and disease-free.